Dificid Launch On Path To Success
This article was originally published in The Pink Sheet Daily
Optimer Pharmaceuticals’ antibiotic Dificid is on track to exceed one-year targets agreed upon with co-promotion partner Cubist.
You may also be interested in...
Optimer Continues Dificid Push In Hospitals With Discount Programs
The antibiotic drug developer has been actively marketing its drug since it was approved last year, but it makes a more concerted effort to address issues of costs in hospitals, it said during at analyst day.
Optimer’s Dificid Gets Medicare Payment “Add-On” For Hospital Patients
In a rare application of its Medicare “new technology add-on payments” policy to drugs, the Centers for Medicare and Medicaid Services announced it will supplement reimbursement to hospitals for the oral antibiotic Deficid and methotrexate toxicity antidote Voraxaze.
Optimer Fires Execs For Questionable Financial Practices
A year after FDA approval of its antibiotic Dificid, the Optimer board has ousted its chairman and at least two other top executives.